JAK1 and Alzheimer disease: Data for topical application in the indication AD are available for tofacitinib (pan-JAKi), ruxolitinib (JAK1/2i) as well as delgocitinib (JAK1/2/3/TYK2i) and cerdulatinib (JAK1/2/3/TYK2/SYKi).